ASX ANNOUNCEMENT 6 June 2024 A$18.7m Osteopore, NDCS and A*STAR project hits key milestones Highlights • Osteopore’s A$18.7m partnership with Singapore’s NDCS and A*STAR to develop next-generation dental implants achieves key milestones. • The project developed a 3D-printing technology which can successfully combine patented biological additives and polymer compounds. • The successful combination of the additives and compounds can speed up bone regeneration. • Adverse reaction testing demonstrated the non-cytotoxicity of successfully combining patented biological additives and polymer compounds. • Testing for osteogenic differentiation revealed enhanced osteogenic differentiation capabilities. • The project is now set to advance to in vivo studies of biological models, to gauge the efficacy of bone regeneration. • The next-generation dental implants provide Osteopore with exposure to the US$27.55 billion global dental bone graft and membrane substitute market. Australian-Singaporean regenerative medicine company Osteopore Limited (ASX: OSX; Osteopore or Company) – a global leader in 3D-printed biomimetic and bioresorbable implants – is delighted to share the exciting progress made by its A$18.7m clinical-industrial partnership with the National Dental Centre Singapore (NDCS) and the Agency for Science, Technology and Research (A*STAR).
OSX Price at posting:
5.4¢ Sentiment: None Disclosure: Held
